Plus Therapeutics announces accreditation, certification for CNSide Diagnostics

CNSide Diagnostics received a certificate of accreditation from CMS for its lab located in Houston, Texas. Following the recent planned laboratory audit, successful certificate of accreditation deems the lab compliant with Clinical Laboratory Improvement Amendments regulations enforced by the Centers for Medicare & Medicaid Services, which are federal standards for laboratories performing testing on human specimens. “This is a key milestone on our trajectory to bring the CNSide cerebrospinal fluid assay platform to the broadest possible set of patients with or at risk for CNS cancers and simultaneously underscores our commitment to the highest quality standards,” said Russ Bradley, CNSide Diagnostics President. “Furthermore, accreditation is the latest tangible accomplishment in our U.S. market access and launch strategy.”